source
- Celcuity receives FDA approval for Revtorpyk breast cancer therapyCelcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…
- Bipartisan Bill to Limit US Biotech Deals with China Remains in LimboA bipartisan bill introduced in the House seeks to bar U.S. biotechnology firms from entering into collaborations or licensing agreements with Chinese companies. The proposal sparked strong reacti…